D000998Chemicals & DrugsD27.505.954.122.3881355080.732419Antiviral Agentsprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonMichaelCharltonMichael Charlton0.000000000000000.000000000000003423Charlton, MichaelProfessor15.91920.00340096135research area of0.9223380.00464347491subject area forMedicine-Gastroenterology34272291Cole SW, Cacioppo JT, Cacioppo S, Bone K, Del Rosso LA, Spinner A, Arevalo JMG, Dizon TP, Capitanio JPProceedings of the National Academy of Sciences of the United States of AmericaThe Type I interferon antiviral gene program is impaired by lockdown and preserved by caregiving. Proc Natl Acad Sci U S A. 2021 07 20; 118(29).Proc Natl Acad Sci U S A2021-07-20T00:00:002021The Type I interferon antiviral gene program is impaired by lockdown and preserved by caregiving.34285133Drayman N, DeMarco JK, Jones KA, Azizi SA, Froggatt HM, Tan K, Maltseva NI, Chen S, Nicolaescu V, Dvorkin S, Furlong K, Kathayat RS, Firpo MR, Mastrodomenico V, Bruce EA, Schmidt MM, Jedrzejczak R, Muñoz-Alía MÁ, Schuster B, Nair V, Han KY, O'Brien A, Tomatsidou A, Meyer B, Vignuzzi M, Missiakas D, Botten JW, Brooke CB, Lee H, Baker SC, Mounce BC, Heaton NS, Severson WE, Palmer KE, Dickinson BC, Joachimiak A, Randall G, Tay SScience (New York, N.Y.)Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021 08 20; 373(6557):931-936.Science2021-07-20T00:00:002021Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.34509862Gupta Y, Kumar S, Zak SE, Jones KA, Upadhyay C, Sharma N, Azizi SA, Kathayat RS, Herbert AS, Durvasula R, Dickinson BC, Dye JM, Rathi B, Kempaiah PBioorganic & medicinal chemistryAntiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Bioorg Med Chem. 2021 10 01; 47:116393.Bioorg Med Chem2021-09-04T00:00:002021Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.35050692Nguyen LC, Yang D, Nicolaescu V, Best TJ, Gula H, Saxena D, Gabbard JD, Chen SN, Ohtsuki T, Friesen JB, Drayman N, Mohamed A, Dann C, Silva D, Robinson-Mailman L, Valdespino A, Stock L, Suárez E, Jones KA, Azizi SA, Demarco JK, Severson WE, Anderson CD, Millis JM, Dickinson BC, Tay S, Oakes SA, Pauli GF, Palmer KE, National COVID Cohort Collaborative Consortium, Meltzer DO, Randall G, Rosner MRScience advancesCannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci Adv. 2022 Feb 25; 8(8):eabi6110.Sci Adv2022-02-23T00:00:002022Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses.36708269Pettit NN, Imam S, Sherer R, Hazra AInternational journal of STD & AIDSTreatment options for severe or refractory mpox virus infection in patients with advanced HIV. Int J STD AIDS. 2023 05; 34(6):366-373.Int J STD AIDS2023-01-28T00:00:002023Treatment options for severe or refractory mpox virus infection in patients with advanced HIV.BSD MicrobiologyUniversity of ChicagoRichardWhitleyRichard Whitley41.78927490000000-87.601250000000001238Whitley, RichardAndrewAronsohnAndrew Aronsohn41.78927490000000-87.601250000000001306Aronsohn, AndrewAssociate ProfessorRonenBorensteinRonen Borenstein41.78927490000000-87.60125000000000423Borenstein, RonenPostdoctoral Scholartrue1true1Postdoctoral ScholarPostdoctoral Scholartrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate ProfessorAnjanaPillaiAnjana Pillai0.000000000000000.000000000000003399Pillai, AnjanaAssociate Professor